Education
About Us
Working with TipRanks
Follow Us
Biomea Fusion (BMEA)
NASDAQ:BMEA
BMEA Stock Chart & Stats
$1.37
$0.07(1.75%)
At close: 4:00 PM EST
$1.37
$0.07(1.75%)
Day’s Range― - ―
52-Week Range$1.29 - $12.85
Previous CloseN/A
Volume309.16K
Average Volume (3M)2.40M
Market Cap
$89.09M
Enterprise Value$23.96M
Total Cash (Recent Filing)$46.64M
Total Debt (Recent Filing)$6.88M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Apr 06, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding70,703,636
10 Day Avg. Volume5,869,688
30 Day Avg. Volume2,395,415
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-1.16
Enterprise Value/Market Cap0.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-47.93
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$7.33Price Target Upside435.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trials And EfficacyThe company's expectation to initiate the Phase 2 COVALENT-212 study is based on meaningful reductions in HbA1c, emphasizing its clinical promise.
Market Potential And StrategyAnalyst maintains a Buy rating with a high-risk short-term view, indicating confidence in potential upside.
Regulatory And Development ProgressOngoing confirmatory Phase 2 COVALENT-211 and COVALENT-212 trials should support regulatory alignment for later-stage development in defined T2D subtypes.
Bears Say
Biomarkers And Validation52-week data lack mechanistic biomarkers that can validate icovamenib’s long-term disease-modifying potential.
Stock PerformanceBMEA stock was down ≈30% following the disclosure of the 52-week COVALENT-111 data.
Trial Design And Patient SelectionThe T2D subtype framework used in the trial is not routinely applied in clinical practice, complicating patient selection.
Biomea Fusion News
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $1.29 and its highest was $12.85 in the past 12 months.
What is Biomea Fusion’s market cap?
Biomea Fusion’s market cap is $89.09M.
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is Apr 06, 2026 which is in 148 days.
How were Biomea Fusion’s earnings last quarter?
Biomea Fusion released its earnings results on Nov 04, 2025. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.256 by -$0.014.
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate is -0.23.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 70,703,636 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Biomea Fusion reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.256. Following the earnings report the stock price went up 6.349%.
Which hedge fund is a major shareholder of Biomea Fusion?
Currently, no hedge funds are holding shares in BMEA
Biomea Fusion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.33 (435.04% Upside)
$7.33 (435.04% Upside)
Hedge Fund Trend
Increased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 13.6%
Last 30 Days ▲ 13.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.77%
12-Months-Change
Fundamentals
Return on Equity
-209.00%
Trailing 12-Months
Asset Growth
-46.27%
Trailing 12-Months
Company Description
Biomea Fusion
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
BMEA Stock 12 Month Forecast
Average Price Target
$7.33
▲(435.04% Upside)
Technical Analysis
Ownership Overview
8.63% Insiders
8.66% Mutual Funds
<0.01% Other Institutional Investors
79.60% Public Companies and
Individual Investors